医療薬学
Online ISSN : 1882-1499
Print ISSN : 1346-342X
ISSN-L : 1346-342X
ノート
SGLT2阻害薬に対する院内採用の評価と使用基準の活用による適正使用支援の有用性に関する検討
佐村 優小川 寿子仙内 光子堀 慎太郎山本 彩子腰岡 桜廣瀬 直樹関根 寿一
著者情報
ジャーナル フリー

2017 年 43 巻 2 号 p. 80-93

詳細
抄録

Information on the efficacy and safety of new medicine is limited because clinical trials are performed in a limited population. Thus, we evaluated Phase III trials and the pharmaceutical and medical device agency's review reports and risk management plans at Yokohama General Hospital. Moreover, pharmacists evaluated the patient applications for new medicine. We support appropriate pharmacotherapy to evaluate adopted medicines through these activities. Moreover, following the adoption of medicines at our hospital, we form criteria for prescribing high-risk medicines and support appropriate pharmacotherapy. In this study, we evaluated and supported the risk factors of sodium glucose cotransporter 2 (SGLT2)-inhibitors as dehydration (particularly in elderly patients for concomitant diuretic use), urinary tract infection, and genital infection for appropriate use. Furthermore, we developed criteria for prescribing SGLT2-inhibitors, at patient limited and evaluating adopted medicines. We established the endpoints of support by pharmacists as the rate of patient inclusion criteria and pharmacists' intervention for patient inclusion criteria. As a result, the rates of patient inclusion criteria were 43.3% (8/17) and 53.3% (8/15) patient limited and evaluating adopted medicines, respectively. After the pharmacists' intervention, SGLT2-inhibitor was not prescribed to one patient with a history of cerebral infarction and congestive heart failure. Furthermore, as a result of consultations and careful administration for fifteen patients by physicians and pharmacists, severe adverse events were not reported in these patients. We suggest that it was effective to support appropriate pharmacotherapy evaluation of adopted medicines and drug information and form criteria for appropriate use at our hospital.

著者関連情報
© 2017 日本医療薬学会
前の記事 次の記事
feedback
Top